Bayer's Christmas Court Date and the Cash-Flow Test That Outranks Every Drug Approval
Published on 11/18/2026 at 22:01 | Editorial boerse-global.deBayer investors are being asked to weigh two very different kinds of progress this winter: regulatory wins in the pharmacy and a courtroom verdict in Missouri. Neither one, on its own, settles the question of whether the shares deserve more confidence after a 51% climb since the start of the year.
The legal side has a firm deadline attached. Chief executive Bill Anderson told Reuters in November that Bayer expects a court ruling on its proposed $7.25 billion Roundup settlement before Christmas, with a Missouri court currently reviewing the deal. A green light would reduce uncertainty hanging over that proposal — but it cannot be booked in advance, and it does nothing to generate recurring earnings.
What the pipeline has actually delivered
On the commercial front, the approvals are already in hand. Bayer won Chinese clearance on 4 November for Sevabertinib as a first-line treatment for adults with advanced HER2-mutated non-small cell lung cancer, backed by data from the ongoing Phase I/II SOHO-01 trial. Later the same month, Asundexian was cleared in the US under the brand name Sunharbo for certain adults following a non-cardioembolic ischemic stroke or high-risk TIA, given alongside antiplatelet therapy. Bayer bills it as the first factor XIa inhibitor approved anywhere in the world.
Those are regulatory facts. Turning them into revenue and profit is a separate exercise, and that distinction is where the investment case gets interesting.
Should investors sell immediately? Or is it worth buying Bayer?
Free cash flow is the yardstick that matters
When Bayer reported quarterly results, it lifted its outlook for the Pharmaceuticals margin along with expectations for group EBITDA before special items and free cash flow, while projecting lower net financial debt. The operating base behind that guidance: third-quarter 2026 group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion.
A raised forecast signals improved confidence from management, not proof of future cash generation. Whether Bayer actually delivers the promised financial improvement is now the test — and further approvals would strengthen the picture mainly if they eventually show up in the numbers.
The sell side is split down the middle
Deutsche Bank Research lifted its price target to EUR 65 from EUR 60 on 10 November and kept its buy rating, with analyst Virginie Boucher-Ferte raising EBITDA and EPS estimates for the next two years following the quarterly figures. UBS followed a similar line, confirming its buy recommendation on 4 November and raising its target to EUR 66; analyst Matthew Weston pointed to strong quarterly results and, in particular, the continued Pharmaceuticals division.
Berenberg moved in the opposite direction on conviction, even as it raised its target to EUR 62.00 from EUR 53.50. The rating stayed at "Hold." Analyst Sebastian Bray acknowledged the strong share-price year but drew no buy call from it — and flagged a possible listing of Monsanto toward the end of the decade, with proceeds potentially benefiting the pharma division. That is a long-term financing option, not a source of funds available today; neither the listing nor any use of proceeds should be treated as a done deal.
Berenberg's numbers frame the bull case precisely: it sees EUR 5 billion in EBITDA for Bayer's pharma division in 2027, against a market consensus of EUR 4.8 billion. Nubeqa and Kerendia are named as the drivers. An analyst estimate, though, is neither a company target nor earned profit — and a higher earnings forecast sitting comfortably beside a hold rating is not a contradiction. The business can improve while the stock has already priced in much of that improvement.
The earnings picture is improving, not fixed
The third quarter of 2026 showed earnings per share of -EUR 0.69, better than -EUR 0.98 a year earlier but still negative. Revenue rose to EUR 10.05 billion from EUR 9.66 billion. That supports the narrative of operational recovery without answering whether future earnings will clear the more demanding expectations now embedded in the valuation. Group EPS and divisional EBITDA describe different levels of the business, and treating an optimistic divisional estimate as proof of company-wide earnings security would be a stretch.
Bayer at a turning point? This analysis reveals what investors need to know now.
The bear case, then, is not that pharma stops growing — it is that growth lands short of the bullish analyst view. After a year like this one, even a solid performance might not be enough to justify fresh upside.
Two dates to circle
The next hard checkpoint is fourth-quarter 2026 results, expected on 24 February 2027, when investors will look for evidence that Bayer can underpin the higher pharma expectations operationally. Before that comes the Missouri ruling.
Until Bayer backs its upgraded guidance with real cash and the court review reaches its conclusion, the gap between confirmed regulatory success and financial impact still to be earned remains the line that separates the two sides of this trade.
Ad
Bayer Stock: New Analysis - 18 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
